X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

NICE Asks Gilead To Lower Trodelvy Rate And Bans Eczema Meds

Content Team by Content Team
12th April 2022
in News
NICE Asks Gilead To Lower Trodelvy Rate And Bans Eczema Meds

The United Kingdom’s drug price watchdog had a bad week. The National Institute of Health and Care Excellence has denied Gilead Sciences’ Trodelvy for usage against triple negative breast cancer in preliminary recommendations, claiming that it is too expensive for the NHS to utilise.

The National Institute for Health and Care Excellence (NICE) has dismissed three atopic dermatitis drugs—Rinvoq from AbbVie, Pfizer’s Cibinqo, and Leo Pharma’s Adtralza—in a separate ruling. According to NICE, the decision has no impact on patients who are currently receiving the therapy. Firstly, when it comes to Trodelvy, the guidance establishes a coverage gap with Scotland, which has approved the treatment. Trodelvy has been demonstrated to survive longer than chemotherapy in triple-negative breast cancer (TNBC) patients.

The draft guidance is followed by a three-week public feedback period. Meanwhile, Gilead has been given the task of lowering Trodelvy’s price by NICE. They are taken aback since this price signifies they cannot stress it for use in the NHS at this time, given the dearth of therapy choices for women with this form of breast cancer, said Helen Knight, interim head of medicine evaluation at NICE, in a statement. They hope the corporation will think about what it can do to help NICE approve a treatment that could allow patients with significant triple negative breast cancer to spend more time with their loved ones.

According to NICE, 2,000 women in England have TNBC, with 650 of them being eligible for Trodelvy if they are cleared. The use of Roche’s Tecentriq in combination with chemotherapy is recommended by NICE for TNBC. Gilead described the decision as “very disappointing,” adding that the United Kingdom is really the only Project ORBIS nation that does not cover the treatment. Gilead stated that it would engage with NICE to reach an agreement before the May 10 conference.

Gilead will work closely with NICE to resolve doubts raised about cost-effectiveness estimates, according to the company. They feel they have made a compelling, cost-effective case for SG reimbursement in England, and that they are genuinely worried about the possibility of unnecessary delay, particularly in a cancer case where every day counts. NICE says there is ambiguity about the efficiency of atopic dermatitis medications as compared to other authorised topical therapies such as lotions and corticosteroids. Immunosuppressants like methotrexate and ciclosporin, as well as targeted treatments like Sanofi’s Dupixent and Lilly’s Olumiant, are also approved for use.

Due to the shortcomings in clinical data, the economic model’s findings are also highly unclear, NICE noted. As a result, determining the cost-effectiveness of the medications is difficult. NICE has asked for further information in order to analyse cost effectiveness, and will meet next month to do so.

Previous Post

Major Success Factors For Clinical Development Organizations

Next Post

The US Intends To Implement Federal Employee Vaccination Law

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
The UK begins the biggest ever immunization program

The US Intends To Implement Federal Employee Vaccination Law

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In